Precision Medicine Market to Reach US$ 105.6 Billion by 2026, Globally |CAGR: 9.9%| UnivDatos Market Insights

NOIDA, India, Dec. 1, 2020 /PRNewswire/ — A comprehensive overview of the precision medicine market is recently added by UnivDatos Market Insights to its humongous database. The precision medicine market report has been aggregated by collecting informative data of various dynamics such as market drivers, restraints, and opportunities. Furthermore, the precision medicine market report offers a detailed analysis of the latest industry developments and trending factors in the market that are influencing the market growth. Furthermore, this statistical market research repository examines and estimates the precision medicine market at the global and regional levels. Global Precision Medicine Market is expected to grow at a CAGR of 9.9% from 2021-2026 to reach US$ 105.6 billion by 2026.

Market Overview

Precision medicine is known to be one of the most promising approaches for tackling the diseases that have thus far eluded effective treatments or cures. Several indications such as cancer, neurodegenerative diseases, and rare genetic conditions take an immense toll on individuals, families, and societies. Cancer is amongst the leading cause of mortality worldwide with an estimation of 9.6 million deaths in 2018. The most common cancers include lung (2.09 million cases), breast (2.09 million cases), colorectal (1.80 million cases), prostate (1.28 million cases), non-melanoma skin (1.04 million cases), stomach (1.03 million cases).

The rising demand for preventive care and advances in next-generation sequencing (NGS) technologies have resulted in an unprecedented proliferation and deluge of genomic sequence data, thereby driving the market growth of the precision medicine sector. In the last 15 years, the cost of mapping a human genome has fallen from US$ 100 million to below US$ 1,000, allowing the use of data from patient DNA to become a significant viable method to provide precise, actionable recommendations before symptoms occur. The growth of the industry is also fueled by scientific discovery, alignment of incentives, regulatory decisions, consumer interest and demand, and advances in technology. The growth of the market for precision medicine is also supported by the increasing patient adherence to treatment and rising prevalence of oncology indications.

Request Sample Copy of this Report @ https://univdatos.com/report/precision-medicine-market-current-analysis-and-forecast-2020-2026

Impact of COVID-19:

As the pandemic is spreading rapidly, clinicians treating COVID-19 are in desperate need of effective therapy, as the development of an effective vaccine remains a remote possibility. Given the urgent nature of the pandemic and the number of companies and researchers developing COVID-19 related therapies, there are more than 560 drug development programs in the pipeline with over 370 trials been reviewed by FDA. For instance, Boehringer Ingelheim initiated a Phase II study of BI 764198, a TRPC6 inhibitor to alleviate the damage to the lung and decrease the risk or severity of acute respiratory complications in patients hospitalized for COVID-19.

Ask for Price & Discounts @ https://univdatos.com/report/precision-medicine-market-current-analysis-and-forecast-2020-2026

Global Precision Medicine Market report is studied thoroughly with several aspects that would help stakeholders in making their decisions more curated.

By Technology, the market is primarily bifurcated into

  • Big Data Analytics
  • Bioinformatics
  • Gene Sequencing
  • Drug Discovery
  • Companion
Read more

At a CAGR of 10.1% Lateral Fitness Equipment to Reach $10.7 Billion by 2027

(MENAFN – EIN Presswire) https://img.einpresswire.com/large/167817/lateral-fitness-equipment-marke.jpeg#790×466

Lateral Fitness Equipment Market

Market to witness significant growth due to introduction of high-tech technology such as television screen, CSAFE connectivity, iPod compatibility, sound system

Surge in number of gym memberships, rise in sale of in-home equipment, upsurge in urban population & increase in government initiatives to promote healthy life is further boost the overall revenue. — SwatiPORTLAND, OR, UNITED STATES, December 1, 2020 /[To enable links contact MENAFN] EINPresswire.com/ — According to a new report published by Allied Market Research, titled, ‘[To enable links contact MENAFN] Lateral Fitness Equipment Market by Type, Body Type, End User, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2020–2027,’ the global lateral fitness equipment market size was valued at $5.4 billion in 2020, and is projected to reach $10.7 billion by 2027, registering a CAGR of 10.1% from 2020 to 2027. Lateral fitness equipment is any machine or device required for physical exercise to manage overall weight, improve physical stamina, and develop muscular strength. Lateral fitness equipment market demand has increased globally, due to increase in health awareness. In addition, physical exercise is advised during certain medical treatments. The most commonly used lateral fitness equipment include treadmills, elliptical, stationary bicycles weightlifting machines & strength building machines, and others.Increase in health awareness and rise in need for active, healthy lifestyle across the world majorly boost the growth of the lateral fitness equipment market. Sedentary lifestyle and changes in eating habits have led to increase in health risks. Therefore, increase in awareness toward regular physical activities to maintain healthy lifestyle fuels the growth of the lateral fitness equipment market.

Moreover, availability of smart gym equipment has made the lateral fitness exercises interesting and entertaining. Smart gym equipment is a type of equipment that is connected to an app that records workouts and also displays the data about workout. These connected gym equipment are linked to the internet and record all data such as workout goals, nutritional habits, and health history through cloud based data. This data helps in creating a personalized exercise plan and also track the workout. Furthermore, implementation of technologies like IoT and AI in lateral fitness equipment help connect the machines with smartphone, which also augment the growth of lateral fitness equipment market. In addition, treadmills, elliptical, and stationary bikes are the most popular high-tech lateral fitness machines owing to the presence of television screens, Bluetooth connectivity, iPod compatibility, sound system, CSAFE connectivity and other features. Thus, increase in implementation of high-tech features is anticipated to provide lucrative lateral fitness equipment market opportunity and eventually increase its customer base.

Download PDF Sample Report @ [To enable links contact MENAFN]

The number of social media users has increased considerably with rise in internet penetration. Taking this into consideration, most of the key players in the lateral fitness equipment market strategize on promoting their products and services on these social media platforms. Social media marketing is one of the major strategies adopted by various companies and

Read more

Telix Pharmaceuticals Limited Acquires TheraPharm GmbH, Broadening Reach to Hematologic Cancers and Transplant Medicine

MELBOURNE, Australia and BAAR, Switzerland, Nov. 29, 2020 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces it has entered into an agreement with Scintec Diagnostics GmbH (‘Scintec’) to acquire TheraPharm GmbH (‘TheraPharm’), a Swiss-German biotechnology company developing innovative diagnostic and therapeutic solutions in the field of hematology.

The acquisition of TheraPharm provides Telix with access to a portfolio of patents, technologies, production systems, clinical data and know-how in relation to the use of Molecularly Targeted Radiation (MTR) in hematology and immunology. TheraPharm is developing antibody MTR technology against CD66, a cell surface target highly expressed by neutrophils (a type of white blood cell) and tumor-infiltrating lymphocytes. As such, the technology has potentially very broad applications in the diagnosis and treatment of hematologic diseases (e.g. blood cancers), lymphoproliferative disorders and immune-mediated diseases (e.g. lupus, and multiple sclerosis). Of particular interest is the demonstrated use of the technology to safely and effectively perform bone marrow conditioning (BMC) prior to bone marrow stem cell transplant.

Telix CEO, Dr. Christian Behrenbruch stated, “Telix is committed to extending and improving the lives of patients with serious diseases. As such, the acquisition of TheraPharm and its MTR assets are uniquely aligned to Telix’s mission and technical strengths in antibody engineering and radiochemistry. TheraPharm’s technology has a significant role to play in BMC and stem cell transplantation across a broad range of blood cancers and rare diseases. The current approach to BMC employs highly toxic drugs that have a poor morbidity and mortality profile, and for which many patients are ineligible. MTR offers an excellent safety profile that may greatly expand the number of patients able to undergo life prolonging stem cell transplantation while greatly reducing the hospitalisation burden and cost associated with such procedures.”

TheraPharm co-founder and Managing Director, Dr. Klaus Bosslet added, “Over the past 5 years, TheraPharm, in collaboration with Dr. Kim Orchard from the University of Southampton (UK), has made excellent progress developing 90Y-besilesomab for the treatment of hematologic cancers and several related conditions including multiple myeloma, leukemia and amyloidosis. This unique asset is a logical addition to Telix’s portfolio, offering a potentially rapid development path to a first commercial indication for the treatment of patients with SALA, while at the same time having potentially broad applications for stem cell transplantation in patients with more common cancers of the blood, including multiple myeloma and leukemia. We look forward to joining the Telix team in order to expedite the development of products for this under-served field.”

Full transaction details, including financial terms, can be found via the Telix website and ASX portal here.

About Hematopoietic Stem Cell Transplant (HSCT)

Bone marrow conditioning (BMC) followed by hematopoietic stem cell transplantation (HSCT) is presently performed to treat patients with hematologic malignancies (blood cancers), with the objective of extending patient survival or achieving cure. HSCT is also performed for a broad range of non-cancer conditions. HSCT is preferentially performed in countries of high income (Europe >30,000, Americas >20,000, worldwide >65,000 p.a., respectively)

Read more

Global fitness app market size valuation to reach USD 15.96 billion by 2026

Selbyville, Delaware, Nov. 24, 2020 (GLOBE NEWSWIRE) — As per reliable estimates, worldwide fitness app market size is predicted to reach USD 15.96 billion mark by 2026. Rising concerns associated with unhealthy habits, evolving consumer lifestyle, and growing obese population are some of the key factors propelling the market expansion.

The study elaborates on several market segmentations including app type, device type, OS platform type, and regional outlook. Additionally, the document conducts a thorough SWOT analysis of various companies operating in this business sphere.

The research report also analyzes the impact of COVID-19 outbreak on industry expansion graph and valuation in the ensuing years, further allowing for advanced decision-making during investment assessment.

Request Sample copy of this Report @https://www.marketstudyreport.com/request-a-sample/1695317/

The surge in obese population coupled with rising adoption of sedentary lifestyle have resulted in increased pervasiveness of diseases such as hypertension and diabetes. In addition to this, rising per capita income along with increasing awareness pertaining to health and nutrition are stimulating the overall industry outlook.

According to industry analysts, the number of gym and health club memberships has significantly increased in the recent past. Additionally, rising smartphone penetration, widespread adoption of mobile devices, and easy accessibility to high-speed internet are positively impacting the remuneration scale of global fitness app market.

Availability of numerous types of fitness apps such as Sweat: Kayla Itsines Fitness and Runstatic coupled with high concentration of companies are also facilitating the business scenario. In 2015 for instance, Adidas acquired the Austrian company Runstatic in order to improve its overall market share. Thus, focus among major companies towards expanding their product portfolio through innovative launches and strategic collaborations are aiding the expansion of global fitness app market.

Highlighting the regional outlook

Global fitness app industry is bifurcated into North America, Asia-Pacific, Europe, Latin America, and Middle East & Africa. According to authentic estimations, North America is expected to capture majority market share by the year 2026.

Growing population and surging disposable income are favoring the regional market outlook. Moreover, widespread adoption of sedentary lifestyle and rising health concerns have augmented the demand for fitness apps, which in turn is positively swaying the business dynamics in North America.

Meanwhile, Asia-Pacific fitness app market is set to record the highest CAGR through 2026. Factors such as growing purchasing power, rising health cognizance, high concentration of fitness centers, and increasing smartphone penetration have allowed Asia-Pacific to emerge as a major revenue generator for worldwide fitness app market.

To access a sample copy or view this report in detail along with the table of contents, please click the link below:

https://www.marketstudyreport.com/reports/fitness-app-market-share-size-trends-industry-analysis-report-by-app-type-fitness-and-activity-tracking-diet-and-nutrition-by-device-type-smartphones-tablets-wearable-devices-by-gender-by-os-platform-by-region-segment-forecast-2018-2026

Global Fitness App Market by App Type (Revenue, USD Billion, 2015-2026)

  • Medication Adherence
  • Lifestyle Management
  • Nutrition & Diet
  • Disease Management
  • Workout & Exercise Apps

Global Fitness App Market by Device Terrain (Revenue, USD Billion, 2015-2026)

  • Wearable Devices
  • Tablets
  • Smartphones

Global Fitness App Market by OS Platform (Revenue, USD Billion, 2015-2026)

Global Fitness App Market Regional Outlook (Revenue, USD Billion, 2015-2026)

North America

Europe

  • Netherlands
  • Russia
  • Belgium
  • Spain
Read more

Online Fitness Market Size to Reach USD 59,231 Billion by 2027 | CAGR of 33.1%

BANGALORE, India, Oct. 29, 2020 /PRNewswire/ — Online/Virtual Fitness Market by Streaming Type (Live, and On-demand), Device Type (Smart TV, Smartphones, Laptops Desktops & Tablets, and Others), Session Type (Group and Solo), Revenue Model (Subscription, Advertisement, and Hybrid) and End User (Professional Gyms, Sports Institutes, Defense Institutes, Educational Institutions, Corporate Institutions, Individuals, and Others): Global Opportunity Analysis and Industry Forecast, 2020-2027 – Published on Valuates Reports in Beauty & Fitness Category.

Valuates Reports Logo

The global Online fitness market size was valued at USD 6,046 Million in 2019 and is projected to reach USD 59,231 Million by 2027, growing at a CAGR of 33.1% from 2020 to 2027.

North America is expected to hold the largest Online Fitness Market share during the forecast period. The major factor driving the growth of North America’s market share is the increased emphasis on precision medicine and personalized treatment and the significant presence of numerous health and wellness organizations across this region.

Major factors driving the growth of online fitness market size are the need for specialized fitness sessions to achieve physical fitness, the interest of health insurance companies in online fitness services to minimize the cost of health insurance, increasing demand for fitness based on AR or VR, growing demand for healthy food.

Furthermore, recent COVID-19 has had a positive effect on the online fitness market size. The COVID-19 pandemic has disrupted people’s lives and forced fitness centers to remain closed. This scenario has, in turn, led to the rapid adoption of virtual fitness solutions as individuals have begun workouts at their homes.

Request a Sample Copy of the Report For COVID-19 Impact Analysis on Online Fitness Market: https://reports.valuates.com/request/sample/ALLI-Manu-0V29/online_fitness_industry

TRENDS INFLUENCING THE ONLINE FITNESS MARKET SIZE

The increase in digitalization will propel the expansion of the online fitness market size along with the trend of connected fitness equipment that allows users to monitor health parameters, such as pulse rate and calories. Several businesses are launching virtual classes that allow users to incorporate fitness experiences with their smart devices.

The rising penetration of smart devices and the internet is expected to increase the growth of the online fitness market size. The penetration of smartphones and tablets has resulted in high fitness app adoption across all demographics. Some apps provide personalized services based on specifications and body physiology.

Corporate institutions that incorporate gyms into their infrastructure would boost the demand for the online fitness industry. Several fitness clubs partner with businesses to facilitate the introduction of gyms to improve employee productivity in the work environment.

Awareness about the growing health issues due to sedentary lifestyles is fueling the online fitness market size. Increasing rates of obesity and associated disorders, including heart attacks and diabetes, enable individuals to take individual fitness lessons to cope with specific health problems.

However, interruptions in the class flow due to tech glitches, along with the lack of real contact with the teacher, may, to some degree, impede the growth of the online fitness industry.

View market snapshot before purchasing

ONLINE FITNESS

Read more

England’s daily death toll could reach 422

Young man and young woman in urban environment using protective face masks
Coronavirus cases are on the rise throughout England, despite the wearing of face coverings being enforced in many enclosed public spaces. (Posed by models, Getty Images)

England’s coronavirus death toll could reach up to 422 on 5 November, a report has suggested.

Nations throughout Europe are in a dreaded second wave of the infection, prompting French president Emmanuel Macron to announce a second national lockdown until at least the end of November.

The UK government is resisting the extreme measure, despite Imperial College London scientists estimating nearly 100,000 people are catching the coronavirus every day in England alone.

The number of new daily cases is somewhat muddled, however, with a team from the University of Cambridge reporting 55,600 new infections are likely occurring a day in England.

Read more: Long COVID may cause skin symptoms

With hospitalisations and deaths inevitably following a surge in cases, the Cambridge scientists predict between 237 and 422 people will die with the coronavirus on 5 November, just one week away.

On 28 October, 24,701 people tested positive for the infection in the UK, with 310 patients dying within 28 days of a swab.

Doctor in protective gloves & workwear holding Testing Kit for the coronavirus test. The doctor is collecting nasal sample for a young lady with a sampling swab.
Tens of thousands of new infections are being confirmed every day, however, people without symptoms may not know to get tested. (Posed by a model, Getty Images)

The number of new coronavirus cases cannot be determined with absolute certainty.

Some patients do not develop the infection’s tell-tale fever, cough or loss of taste or smell, and therefore do not know to get swabbed.

Read more: Coronavirus patients over 65 in the UK can test drugs at home

This is particularly true among young people and children, who may unwittingly spread the infection, not knowing to isolate.

Delays to test results may also mean people who could have been exposed to the coronavirus continue to mix with others.

Watch: Can you catch coronavirus twice?

To better understand England’s daily rate of new infections, the Cambridge scientists analysed a range of data sources, including Public Health England and the Office for National Statistics.

Writing in the report COVID-19: Nowcast And Forecast, the team found the North West and North East are likely the worst affected regions, with a predicted 17,600 new infections a day. Yorkshire comes in second, with an estimated 14,800 new cases every 24 hours.

“Note a substantial proportion of these daily infections will be asymptomatic,” wrote the scientists.

The virus’ reproduction number, or R, is said to be above one across the country. The scientists predict this with “100% probability” in all regions apart from London.

Read more: 14% of all UK coronavirus deaths linked to air pollution

The R number is the number of people a coronavirus patient is expected to pass the virus on to. When R is above one, an outbreak grows.

The scientists predicted R exceeds one in London with 67% probability. The capital city has the highest “attack rate”, however, defined as the proportion of people who have ever been infected, at

Read more

EPA/DHA (Omega3) Ingredients Market to reach $3.8 billion by 2026, Says Global Market Insights, Inc.

EPA/DHA (Omega3) Ingredients Industry projected to register more than 7% CAGR between 2020 and 2026, impelled by increasing consumer awareness for omega-3 fortified products.

Selbyville, Delaware, Oct. 29, 2020 (GLOBE NEWSWIRE) —

The EPA/DHA (omega3) ingredients market value is expected to cross USD 3.8 Billion by 2026, according to a new research report by Global Market Insights, Inc. Growing awareness about the functional benefits of EPA/DHA ingredients and increasing and increasing health care cost is anticipated to propel the industry outlook.

EPA/DHA (Omega3) Ingredients industry from EPA is expected to register over 8.6% CAGR through 2026, due to the virtue of increasing high quality supplements and increasing product penetration. Since, EPA fatty acid supplements help to support good heart health along with weight management, child development, and joint health. EPA metabolizes to produce hormone like substances called eicosanoids which are responsible regulating cell growth, muscle activity, hormone secretion and blood clotting. Thereby, demand for EPA/DHA(Omega3) ingredients is anticipated to grow. Moreover, rising incidences of various diseases like cardiovascular disease, diabetes and hormonal issues owing to hectic lifestyle and harmful dietary habits will boost product demand.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/118

The global economy is hit by COVID- 19 pandemic where, even after continuing the operations, many nations are facing challenges of resuming their production capacity and manufacturers are experiencing the effect of shortages in their distribution networks. However, increasing electricity demand and robust growth across the healthcare sector is anticipated to amplify the product installation.

Some major findings of the EPA/DHA (omega3) ingredients market report include:

  • The gradual shift of consumers towards dietary and functional food has gain traction owing to its high protein and nutrition content will foster the global Market trends.

  • Increasing incorporation of EPA/DHA ingredients in infant formulas is one of the defining trends which creates favourable market demand.

  • EPA/DHA (omega3) ingredients demand from animal & pet feed is expected to register over 9.8% CAGR through owing to increasing number of pet ownership.

  • High demand of clean label products is creating lucrative growth opportunities for the market.

  • EPA/DHA ingredients sourced from plant such as algae is likely to gain traction in the market due to increasing vegan population.

  • Key players operating in the market are continuously investing in research and development activities in order to monitor its product offerings and exhilarate ever rising demand of consumers.

  • Increasing application scope in cancer treatment may drive the industry demand. Rise in R&D expenditure to develop omega 3 clinical nutrition products and pharmaceutical drugs should have positive influence on product demand.

  • Some of the major players operating in the market are BASF, Koninklijke DSM N.V., Croda International plc, Omega Protein, Nordic Naturals, Inc., Copeinca ASA, Epax Norway AS, Arista Industries, Inc., GC Rieber, Solutex, Olvea and Lysi others.

Browse key industry insights spread across 300 pages with 396 market data tables and 30 figures & charts from the report, “EPA/DHA (Omega3) Ingredients Market Forecasts By Application (Dietary supplements, Pharmaceuticals, Functional Foods, Pet & Animal

Read more

The Asia Pacific liposome drug delivery market is expected to reach US$ 1,562.92 million in 2027 from US$ 759.81 in 2019

The market is estimated to grow with a CAGR of 9. 6% from 2020-2027. The growth of the market is attributed to the some key driving factors such as high incidence of chronic diseases amongst the population, an upsurge in need for non-invasive drug delivery solutions, increasing investments in R&D for pharmaceutical companies.

New York, Oct. 29, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Asia Pacific Liposome Drug Delivery Market Forecast to 2027 – COVID-19 Impact and Regional Analysis By Product ; Technology ; Application, and Country” – https://www.reportlinker.com/p05978829/?utm_source=GNW
However, high expense involved in the development of drug delivery systems is expected to obstruct the growth of the market to a certain extent during the forecast years.

Liposomes are small sphere-shaped artificial vesicles synthesized from cholesterol and phospholipids. They have multiple layers and a diameter range of 0.01 to 5.0 um. They also have hydrophilic and hydrophobic properties which help liposomes to encapsulate hydrophobic and hydrophilic drugs to be delivered to targeted body site. Liposomes provide an assured system for targeted drug delivery and thereby is the factor influencing the Liposome Drug Delivery market size growth. Liposomes are widely used for enclosing all types of drug molecules such as acyclovir, chloroquine diphosphate, paclitaxel, tropicamide, and cyclosporine. Liposomes are used as a drug carrier for drug therapy for many diseases since they are biodegradable and biocompatible. Also, they have many therapeutic properties like anticancer drugs, genetic materials, proteins, vaccines, macromolecules, and thus can be encapsulated in liposomes.

Research and development (R&D) in liposomal drug delivery systems are increasing across the world due to the increasing prevalence of chronic disease.Drug delivery is the process of dispensing a pharmaceutical compound to attain a therapeutic effect in humans.

Liposomal drug delivery offers multiple advantages such as better pharmacokinetics and pharmacodynamics, enhanced therapeutic efficacy, and decreased toxicity making these delivery systems ideal for patients suffering from various chronic conditions.

Death among the population worldwide has increased due to cancer.The targeted drug delivery system delivers the drug in a controlled manner at a preselected bio site.

Nanotechnology-based delivery systems are making a crucial impact on cancer treatment, and the polymers play a key role in the development of Nano particulate carriers for cancer therapy.Some of the major technological advantages involved in the nanotherapeutic drug delivery systems (NDDS) are prolonged half-life, improved bio-distribution, increased circulation time of the drug, controlled and sustained release of the drug, versatility of route of administration, increased intercellular concentration of the drug, and many more.

The liposomal carriers used in nanotechnology drug delivery systems are likely to experience rapid adoption, which in turn is propelling the market growth.

As per the data provided by, European Society for Medical Oncology, China estimated there were 4.3 million new cancer cases and more than 2.8 million cancer deaths in China in 2015, with lung cancer the most common cancer and the leading cause of cancer death. With high incidences and mortality, cancer is the leading cause of death in China and

Read more

The Asia Pacific pulmonary devices market is expected to reach US$ 8,196.82 million by 2027 from US$ 3,661.53 million in 2019

The market is estimated to grow at a CAGR of 10. 6 % during 2019–2027. The growth of the pulmonary devices market in Asia Pacific is attributed to the increasing prevalence of respiratory diseases and growing number of COVID-19 cases.

New York, Oct. 29, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Asia Pacific Pulmonary Devices Market Forecast to 2027 – COVID-19 Impact and Regional Analysis By Type ; Application ; and End User and country” – https://www.reportlinker.com/p05978832/?utm_source=GNW
Factors such as unfavorable reimbursement scenario associated with the pulmonary device are likely to restrain the growth of the market.

Additionally, strategic activities by manufacturers and increasing preference of home care products are likely to fuel the growth of the pulmonary devices market during the forecast period.

Pulmonary or respiratory devices are used to remove mucus and secretions from the respiratory tract. These medical devices are focused on diagnosis, control, treatment, management, and evaluation of the problems associated with respiratory tract.

The higher prevalence of respiratory disorder is mainly due to the decrease in size of the upper airway lumen in aging population.Millions of people suffer from various respiratory diseases; lung diseases are the most common medical conditions.

Smoking, genetic factors, and infections are among the common factors responsible for respiratory diseases. Medical conditions such as asthma and chronic obstructive pulmonary disease (COPD), chronic bronchitis, cystic fibrosis, and lung cancer are among the significant public health burdens.

According to a new Tulane University study published in The Lancet, chronic obstructive pulmonary disease (COPD) is widespread in China with 8.6% of the country’s adult population, i.e. almost 100 million people suffering from the chronic lung disease. Additionally, among India’s 1.31 billion people, about 6% of children and 2% of adults have asthma.

The patients suffering with these respiratory disorders commonly experience difficulty in breathing.Thus, the availability of various pulmonary devices has helped improve the survival rates of the patients suffering from abovementioned medical conditions.

The rising demand for various therapeutic devices among patients with respiratory disorders is expected to augment the growth of the market during the forecast period.

Asia Pacific countries are expected to witness massive challenges due to increasing COVID-19 cases.To manage the COVID-19 outbreak and provide efficient treatment to patients in the region, local medical device companies are ramping up the production of alternative respiratory systems in the Asian countries.

The governments in India and Australia, among others are taking initiative to fulfill the demand of oxygen during COVID-19 pandemic. Thus, the development of these solutions is likely to create a positive impact on market growth in the Asian region.

In 2019, the therapeutic devices segment held the largest share in the market and is expected to retain its dominance till 2027.The multi-modal and multi-functional use of therapeutic devices for a wide range of pulmonary diseases is expected to account for the growth of the therapeutic devices segment over the coming years.

On the other hand, the consumables and accessories segment is expected to witness fastest growth

Read more

Antibiotics Market to Reach $50.37 Billion by 2025 at 2.1% CAGR, Says Allied Market Research

Rise in consumption of antibiotics in low & middle-income countries (LMICs), heavy inflow of investments for R&D activities by biotech companies, and supportive rules & regulations would propel the growth of the global antibiotics market

Portland, OR, Oct. 28, 2020 (GLOBE NEWSWIRE) — The report provides detailed analyses of the top winning strategies, driving forces & opportunities, key market segments, competitive landscape, and strategic developments. As per the report, the global Antibiotics Market  generated $42.33 billion in 2017 and is expected to reach $50.37 billion by 2025, registering a CAGR of 2.1% from 2018 to 2025.

Increasing utilization of antibiotics in low and middle-income countries (LMICs) due to high incidence of severe infections, high capital allocation for R&D activities by biotech companies, and supportive norms and regulations drive the growth of the market. However, development of antibiotic resistance and rise in drug approval costs hinder the market growth. Conversely, discovery of advanced prospect molecules and innovative combination therapies for the treatment of antibiotic-resistant microbial infections would create opportunities for the market in future.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/5072

Beta lactam and beta lactamase inhibitors segment to maintain its dominance by 2025 

The beta lactam and beta lactamase inhibitors segment contributed nearly two-thirds of the total market share in 2017 and is expected to maintain its dominance by 2025. This is due to rise in demand for its effectiveness in treating Gram-positive & Gram-negative bacteria as well as use in the treatment of broad-spectrum of infections. However, quinolones segment would register the fastest CAGR of 4.3% from 2018 to 2025, owing to their characteristics such as remarkable oral bioavailability, good tissue penetration, and high broad-spectrum bactericidal activity, especially in new generation quinolones. The report also analyzes macrolides and others.

Semisynthetic segment to lead throughout the forecast period 

The semisynthetic segment accounted for more than one-third of the total market share in 2017 and will continue to maintain its lead by 2025. This is due to the enhanced coverage and efficacy against a wide range of organisms as well as ease in administration and cost effectiveness as compared to other antibiotics. However, the synthetic segment would register the fastest CAGR of 2.7% from 2018 to 2025 due to high demand for synthetic membrane-targeted antibiotics, broad spectrum activity, rapid bactericidal activity, no cross-resistance with existing antibiotics, and low probability of developing resistance. The report also discusses antibiotics of natural origin.

Broad-spectrum antibiotics segment to be lucrative by 2025 

Broad-spectrum antibiotics segment contributed more than two-thirds of the total market share in 2017. This segment would dominate by 2025, registering the fastest CAGR of 2.4% from 2018 to 2025. This is attributed to the growing demand for broad-spectrum antibiotics to curb widespread antimicrobial resistance. The research also discusses narrow-spectrum antibiotics.

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/5072

Intravenous segment to dominate in terms of revenue during the forecast period  

Intravenous route of administration segment accounted for nearly half of the total market share in 2017, owing to the rise in incidence of severe infections, which

Read more